1. Does Tranexamic Acid Improve Clot Strength in Severely Injured Patients Who Have Elevated Fibrin Degradation Products and Low Fibrinolytic Activity, Measured by Thrombelastography? 
Hunter B. Moore, MD, PhD, Ernest E. Moore, MD, FACS, Michael P. Chapman, MD, Kirk C. Hansen, PhD, Mitchell J. Cohen, MD, FACS, Frederic M. Pieracci, MD, MPH, FACS, James Chandler, BA, Angela Sauaia, MD, PhD 
Journal of the American College of Surgeons 
Volume 229, Issue 1, Pages (July 2019)
DOI: /j.jamcollsurg
Copyright © Terms and Conditions

2. Figure 1
Change in clot strength based on the differential functional fibrinogen thrombelastography. DFI, depletion of fibrinolysis inhibitors
Journal of the American College of Surgeons  , DOI: ( /j.jamcollsurg )
Copyright © Terms and Conditions

3. Figure 2
Differences in survival times between patients with depletion of fibrinolysis inhibitors stratified by fibrinolysis phenotype and whether they (A) did not receive tranexamic acid (TXA) or (B) did receive TXA. Patients who did not receive TXA hyperfibrinolysis had the highest mortality, and in the cohort of patients who received TXA mortality was higher in the shutdown cohort. Contrasting phenotypes, only TXA (p = 0.043) was associated with increased mortality in the physiologic cohort.
Journal of the American College of Surgeons  , DOI: ( /j.jamcollsurg )
Copyright © Terms and Conditions